AMTB vs BCX

AMTB presents a stark contrast between attractive valuation and deteriorating fundamental health. While the stock trades below its Graham Number ($27.18) and Intrinsic Value ($41.89), the Piotroski F-Score of 2/9 indicates significant weakness in financial health. Strong year-over-year earnings growth (57.10%) is offset by sluggish revenue growth (3.30%) and a highly bearish technical trend (10/100). The company is essentially trading at book value (P/B 0.99), making it a value play with high fundamental risk.

The company exhibits extremely weak financial health with a Piotroski F-Score of just 1/9, indicating significant fundamental deterioration. Despite a high dividend yield of 6.72%, the payout ratio of 141.63% is unsustainable, raising concerns about future cuts. Profitability metrics are entirely absent (0.00% margins), and most valuation and financial health data are unavailable, suggesting opacity or structural issues. While the stock has delivered strong price performance over the past year (+46.8%), it trades at a high P/E of 23.04 without corresponding growth or profitability, and lacks any Altman Z-Score to assess solvency risk.